Can a single gene therapy dose restore saliva flow years after radiation?
NCT ID NCT05060341
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This study follows people who received an experimental gene therapy, AAV2hAQP1, for chronic dry mouth caused by past radiation treatment for cancer. Researchers are checking whether the therapy remains safe and whether any improvement in saliva production lasts over time. The goal is to understand the long-term effects of this one-time treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a gene therapy called AAV2hAQP1, designed to help salivary glands produce more saliva
- What this could lead to
- If successful, this could point toward a durable treatment for chronic dry mouth caused by radiation therapy.
- What could go wrong
- This is a small, early-stage follow-up study focused on safety, not proof of effectiveness. The therapy may not improve symptoms for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIATION-INDUCED XEROSTOMIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health
Charlotte, North Carolina, 28209, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02184, United States
-
Health Sciences North - Northeast Cancer Center
Greater Sudbury, Ontario, Canada
-
Leland Stanford Junior University
Stanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.